NCT04485949: An ongoing trial by Imvax
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04485949 |
|---|---|
| Title | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 20, 2023 |
| Completion date | June 30, 2026 |
| Required reporting date | June 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |